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InforMing the PAthway of COPD Treatment
(IMPACT) trial: fibrinogen levels predict risk
of moderate or severe exacerbations
Dave Singh1, Gerard J. Criner2, Mark T. Dransfield3, David M. G. Halpin4, MeiLan K. Han5, Peter Lange6,
Sally Lettis7, David A. Lipson8,9, David Mannino10, Neil Martin11,12, Fernando J. Martinez13, Bruce E. Miller8,
Robert Wise14, Chang‑Qing Zhu7 and David Lomas15*

Abstract
Background: Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with
chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/
vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients with symptomatic COPD at risk of exacer‑
bations. This analysis used IMPACT trial data to examine the relationship between fibrinogen levels and exacerbation
outcomes in patients with COPD.
Methods: 8094 patients with a fibrinogen assessment at Week 16 were included, baseline fibrinogen data were not
measured. Post hoc analyses were performed by fibrinogen quartiles and by 3.5 g/L threshold. Endpoints included
on-treatment exacerbations and adverse events of special interest (AESIs).
Results: Rates of moderate, moderate/severe, and severe exacerbations were higher in the highest versus lowest
fibrinogen quartile (0.75, 0.92 and 0.15 vs 0.67, 0.79 and 0.10, respectively). The rate ratios (95% confidence interval
[CI]) for exacerbations in patients with fibrinogen levels ≥ 3.5 g/L versus those with fibrinogen levels < 3.5 g/L were
1.03 (0.95, 1.11) for moderate exacerbations, 1.08 (1.00, 1.15) for moderate/severe exacerbations, and 1.30 (1.10, 1.54)
for severe exacerbations. There was an increased risk of moderate/severe exacerbation (hazard ratio [95% CI]: highest
vs lowest quartile 1.16 [1.04, 1.228]; ≥ 3.5 g/L vs < 3.5 g/L: 1.09 [1.00, 1.16]) and severe exacerbation (1.35 [1.09, 1.69];
1.27 [1.08, 1.47], respectively) with increasing fibrinogen level. Cardiovascular AESIs were highest in patients in the
highest fibrinogen quartile.
Conclusions: Rate and risk of exacerbations was higher in patients with higher fibrinogen levels. This supports the
validity of fibrinogen as a predictive biomarker for COPD exacerbations, and highlights the potential use of fibrinogen
as an enrichment strategy in trials examining exacerbation outcomes.
Trial registration: NCT02164513
Keywords: Fibrinogen, COPD exacerbations, Pharmacotherapy, COPD
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Background
Chronic obstructive pulmonary disease (COPD), a common disease characterized by persistent respiratory
symptoms and airflow limitation, is associated with a
substantial economic and social burden and was the
third leading cause of death in 2017 worldwide [1, 2]. The
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InforMing the PAthway of COPD Treatment (IMPACT)
study compared once-daily single-inhaler triple therapy
with fluticasone furoate, umeclidinium and vilanterol
(FF/UMEC/VI) with the dual therapies FF/VI and
UMEC/VI in patients with symptomatic COPD at risk of
exacerbations. This study demonstrated that FF/UMEC/
VI resulted in a significantly lower annual rate of moderate/severe COPD exacerbations and greater improvements in both lung function and health-related quality of
life compared with either dual therapy [3].
Forced expiratory volume in 1 s ( FEV1) is a widely used
lung function marker of COPD disease severity, but correlates poorly with symptoms and does not reflect levels of disease activity [2, 4–6]. Patients with more active
COPD disease are more likely to experience faster disease progression; for example, patients with more exacerbations experience a faster decline in lung function [7,
8]. Therefore, alternative and more sensitive biomarkers are needed that are reflective of disease activity, and
may predict future risk of events such as exacerbations.
Fibrinogen is an acute phase soluble plasma glycoprotein that is primarily synthesized in the liver and is converted into fibrin by thrombin during blood coagulation
[4]. Plasma fibrinogen was qualified by the US Food and
Drug Administration (FDA) in 2015 as the first prognostic or enrichment biomarker for exacerbations and/or
all-cause mortality (ACM) in patients with COPD [9, 10].
This validation was based on an analysis of an integrated
study database, which demonstrated that high baseline
fibrinogen levels in individuals with COPD were associated with an increased risk of exacerbations requiring
hospitalization within 12 months and an increased risk
of death within 36 months [11, 12]. Previous research on
a subset of the ECLIPSE cohort indicated that fibrinogen was the most stable of 34 biomarkers assessed over a
period of 3 months, a critical feature for clinically useful
biomarkers [4, 13]. Additionally, fibrinogen is routinely
measured in clinical practice, and therefore appears to be
a practical blood biomarker for systemic inflammation
in COPD [4]. A fibrinogen level of 3.5 g/L has been proposed as a threshold for identifying patients at increased
risk of exacerbations requiring hospitalization and ACM
[11].
This analysis used data collected in the IMPACT trial
to provide further information regarding the association of fibrinogen levels with exacerbations and ACM in
patients with COPD.

Methods
Study design and population

The IMPACT trial (study CTT116855, NCT02164513)
was a Phase III, randomized, double-blind, parallelgroup, multicenter study conducted in 37 countries
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between June 2014 and July 2017. The study design has
been described in detail previously [3]. Briefly, the total
study duration was approximately 55 weeks, consisting of
a 2-week run-in period, 52-week treatment period, and a
1-week safety follow-up period. Study patients were randomized (2:2:1) to receive triple therapy with FF/UMEC/
VI 100/62.5/25 µg, or dual therapy with FF/VI 100/25 µg
or UMEC/VI 62.5/25 µg administered once daily via
the Ellipta dry powder inhaler. Patients continued use
of their existing COPD medications during the run-in
period and were provided with albuterol for use on an asneeded basis (rescue medication) throughout the study.
All patients provided written informed consent. The
study was conducted in accordance with Good Clinical
Practice guidelines and the provisions of the Declaration
of Helsinki and received approval from local institutional
review boards or independent ethics committees.
Inclusion/exclusion criteria have been described previously [3, 14]. Eligible patients were ≥ 40 years of age, with
symptomatic COPD (COPD Assessment Test score ≥ 10)
and either a post-bronchodilator FEV1 < 50% of the predicted normal value and a history of ≥ 1 moderate or
severe exacerbation in the previous year, or a post-bronchodilator FEV1 of > 50 to < 80% of the predicted normal
value and ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the previous year.
The intent-to-treat (ITT) population comprised all
randomized patients, excluding those randomized in
error [14]. The fibrinogen population is a subset of the
ITT population that included patients with a fibrinogen
assessment at Week 16, fibrinogen data were not collected prior to Week 16. Previous work has shown that
treatment with oral steroids or inhaled corticosteroid/
long-acting β2-agonist (ICS/LABA) did not have an effect
on fibrinogen levels [15, 16].
Annual rate of COPD exacerbations and ACM were
analyzed post hoc in the fibrinogen population according
to a fibrinogen threshold: ≥ or < 3.5 g/L and by fibrinogen quartiles (Quartile 1: < 2.780 g/L; Quartile 2: ≥ 2.780
to < 3.280 g/L; Quartile 3: ≥ 3.280 to < 3.830 g/L; Quartile
4: ≥ 3.830 g/L). Analysis of safety was carried out using
fibrinogen quartiles.
Study endpoints

Study endpoints have been described previously, with
the primary endpoint from the IMPACT trial being the
annual rate of moderate/severe exacerbations during
treatment [3, 14]. This analysis assessed the following
endpoints from Week 16: on-treatment exacerbations
(moderate, moderate/severe, severe), on- and off-treatment ACM and on-treatment adverse events of special
interest (AESIs). A moderate exacerbation was defined
as an exacerbation leading to treatment with antibiotics
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or systemic corticosteroids. A severe exacerbation was
one resulting in hospitalization or death. On-/off-treatment deaths were defined as those that occurred after
Week 16 and study treatment stop date and projected
Week 52 date (based on treatment start date) plus 7 days
(inclusive).
This analysis evaluated the association between fibrinogen levels at Week 16 and exacerbations, mortality and
AESIs, in particular cardiovascular (CV) events and
pneumonia. To confirm that Week 16 fibrinogen could
be used as a baseline value for exacerbation analyses,
we assessed the magnitude of the difference in Week
16 fibrinogen between the treatment groups to check
whether fibrinogen levels were affected by treatment.
Furthermore, to assess whether the Week 16 fibrinogen
population was generalizable to all patients we evaluated
exacerbation history between the patients who withdrew
at Week 16 versus those who remained in the study.
Statistical analyses

These post hoc analyses were performed in two stages.
First, baseline characteristics were summarized in the
fibrinogen population using screening and baseline visit
data. Analysis of variance (ANOVA) was used to assess
the magnitude of differences in fibrinogen levels at Week
16 between treatment groups. The Scheffe multiple comparison procedure was used to compare the difference
between treatment groups. The second stage includes all
other analyses. Fibrinogen data collected at Week 16 was
considered as baseline in this post hoc analysis. All analyses were performed using endpoint data from Week 16
onwards. For example, only exacerbations that occurred
after Week 16 were considered as an event in the analysis of COPD exacerbations annual rate and the analysis of
time-to-first COPD exacerbation.
The rate of on-treatment COPD exacerbations (moderate/severe, moderate, severe) was analyzed using a
generalized linear model assuming a negative binomial
distribution. Rate of on-treatment COPD exacerbation
analyses were performed by comparing fibrinogen subgroups (fibrinogen threshold [3.5 g/L] and fibrinogen
quartiles) with combined treatment groups and by comparing treatment groups for each fibrinogen subgroup
(fibrinogen threshold [3.5 g/L] and fibrinogen quartiles).
The time-to-first on-treatment COPD exacerbation
(moderate, moderate/severe, severe) was analyzed using
a Cox proportional hazards model by comparing fibrinogen subgroups with combined treatment groups. The
relationship between exacerbation rate and fibrinogen
was also explored by using fractional polynomials modelling, in which fibrinogen was included as a continuous
variable in the model. The analyses of exacerbation rates
comparing fibrinogen subgroups included covariates of
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treatment group, gender, exacerbation history in the past
12 months (≤ 1, ≥ 2 moderate/severe), smoking status (at
screening), geographical region and post-bronchodilator
percent predicted forced expiratory volume in 1 s (FEV1;
at screening) and fibrinogen quartile group or 3.5 g/L
threshold as applicable. The fibrinogen subgroup analyses of exacerbation rates comparing treatment groups
included covariates of treatment group, gender, exacerbation history in the past 12 months (≤ 1, ≥ 2 moderate/severe), smoking status (at screening), geographical
region and post-bronchodilator percent predicted FEV1
(at screening). Patients were only included in the model
if they had at least 1 day at risk of an on-treatment exacerbation from Week 16. The time at risk excluded any
days after Week 16 when a patient was experiencing an
exacerbation that started on or prior to Week 16. Analysis by continuous fibrinogen level was performed using
fractional polynomials and included covariates of treatment group, gender, exacerbation history (≤ 1, ≥ 2 moderate/severe), smoking status (at screening), geographical
region, post-bronchodilator percent predicted FEV1 (at
screening), FP1, FP2, interaction terms for FP1 by treatment, FP2 by treatment, and with logarithm of time ontreatment post Week 16 as an offset variable. FP1 and
FP2 represent continuous transformations of fibrinogen
at Week 16. Subgroup models by fibrinogen quartile
at Week 16 with the same covariates but excluding FP
terms are overlaid on the plots at the subgroup median
fibrinogen value. Time to on- and off- treatment ACM
was analyzed by calculation of Kaplan–Meier probability
estimates for each fibrinogen subgroup. Adverse events
(AEs), serious adverse events (SAEs) and AESIs were
summarized using descriptive statistics.

Results
Of the 10,355 patients enrolled in the IMPACT study,
8094 had Week 16 fibrinogen data available and were
included in this analysis (Table 1). Demographics and
baseline characteristics were generally similar across
Week 16 fibrinogen quartile or 3.5 g/L threshold subgroups and consistent with the ITT population (Table 1).
Baseline characteristics by fibrinogen subgroup and
treatment arms are presented in Table 1 in Additional
File 1 (quartiles) and Table 2 in Additional File 1 (3.5 g/L
threshold). The median (interquartile range [IQR]) overall (all treatment combined) fibrinogen level at Week 16
was 3.280 (2.780–3.830) g/L.
Week 16 and baseline comparison

Exacerbation history in the 12 months prior to screening was similar between patients who withdrew before
Week 16 and those who remained in the study (Table 3
in Additional File 1). Table 2 summarizes exacerbations
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Table 1 Baseline characteristics and demographics by fibrinogen subgroup at Week 16
Characteristic

Fibrinogen population

ITT
population

Quartile 1
n = 2017
< 2.780a

Quartile 2
n = 2025
≥ 2.780
to < 3.280a

Quartile 3
n = 2002
≥ 3.280
to < 3.830a

Quartile 4
n = 2050
≥ 3.830a

< 3.5 g/L
n = 5045

≥ 3.5 g/L
n = 3049

Total
N = 8094

Total
N = 10,355

Age, years, mean
(SD)

65.2 (8.4)

65.0 (8.3)

65.2 (8.2)

65.5 (8.1)

65.2 (8.3)

65.3 (8.1)

65.2 (8.2)

65.3 (8.27)

Male, n (%)

1516 (75)

1345 (66)

1269 (63)

1356 (66)

3503 (69)

1983 (65)

5846 (68)

6870 (66)

BMI, kg/m2, mean
(SD)

25.4 (5.3)

26.3 (5.8)

27.2 (6.2)

27.6 (6.6)

26.1 (5.6)

27.6 (6.6)

26.6 (6.1)

26.6 (6.1)

Current

554 (27)

676 (33)

787 (39)

785 (38)

1614 (32)

1188 (39)

2802 (35)

3587 (35)

Former

1463 (73)

1349 (67)

1215 (61)

1265 (62)

3431 (68)

1861 (61)

5292 (65)

6768 (65)

1.348 (0.4929)

1.315 (0.4923)

1.275 (0.4833)

1.241 (0.4652)

1.320 (0.4914)

1.251 (0.4716)

1.294 (0.4851)

1.272 (0.4860)

 FEV1% predicted, 48.0 (14.9)
mean (SD)

46.8 (14.6)

45.7 (14.8)

44.4 (14.3)

47.1 (14.8)

44.7 (14.5)

46.2 (14.7)

45.5 (14.8)

 FEV1/FVC ratio,
mean (SD)

0.475 (0.1187)

0.474 (0.1193)

0.473 (0.1192)

0.473 (0.1182)

0.475 (0.1201)

0.474 (0.1189)

0.470 (0.1196)

Smoking status,
n (%)

Lung function
(post-broncho‑
dilator)
 FEV1 (L), mean
(SD)

0.472 (0.1185)

COPD exacerba‑
tions in previous
year, n (%)
Moderate
  0

367 (18)

370 (18)

354 (18)

397 (19)

916 (18)

572 (19)

1488 (18)

1936 (19)

  1

636 (32)

701 (35)

705 (35)

696 (34)

1681 (33)

1057 (35)

2738 (34)

3542 (34)

   ≥ 2

1014 (50)

954 (47)

943 (47)

957 (47)

2448 (49)

1420 (47)

3868 (48)

4877 (47)

Moderate/severe
  0

3 (< 1)

1 (< 1)

1 (< 1)

1 (< 1)

5 (< 1)

1 (< 1)

6 (< 1)

9 (< 1)

  1

883 (44)

909 (45)

912 (46)

925 (45)

2247 (45)

1382 (45)

3629 (45)

4691 (45)

   ≥ 2

1131 (56)

1115 (55)

1089 (54)

1124 (55)

2793 (55)

1666 (55)

4459 (55)

5655 (55)

Severe
  0

1532 (76)

1507 (74)

1500 (75)

1501 (73)

3796 (75)

2244 (74)

6040 (75)

7684 (74)

  1

423 (21)

451 (22)

438 (22)

467 (23)

1088 (22)

691 (23)

1779 (22)

2300 (22)

   ≥ 2

62 (3)

67 (3)

64 (3)

82 (4)

161 (3)

114 (4)

275 (3)

371 (4)

Angina pectoris

50 (2)

75 (4)

73 (4)

80 (4)

161 (3)

117 (4)

278 (3)

342 (3)

Myocardial
infarction

0

0

0

0

0

0

0

1 (< 1)

Angina pectoris

111 (6)

160 (8)

147 (7)

162 (8)

346 (7)

234 (8)

580 (7)

737 (7)

Previous
myocardial
infarction

112 (6)

117 (6)

138 (7)

166 (8)

308 (6)

225 (7)

533 (7)

681 (7)

Current medical
conditions,
n (%)

Cardiovascular risk
factorsb, n (%)

Quartile 1, fibrinogen value < 25th percentile; Quartile 2, fibrinogen value > 25th percentile and < median; Quartile 3, fibrinogen value ≥ median and < 75th percentile;
Quartile 4, fibrinogen value ≥ 75th percentile
BMI body mass index, SD standard deviation

a

Fibrinogen level descriptor (g/L)

b

Risk factors includes past and current events
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Table 2 Exacerbation status up to Week 16 by fibrinogen quartile and withdrawal status
Week 16 fibrinogen data

No Week 16 fibrinogen data

Exacerbation

Quartile 1
N = 2017

Quartile 2
N = 2025

Quartile 3
N = 2002

Quartile 4
N = 2050

Withdrewa
N = 1195

Otherb
N = 1066

Total
N = 10,355

Yes, n (%)

452 (22)

476 (24)

509 (25)

609 (30)

547 (46)

271 (25)

2864 (28)

No, n (%)

1565 (78)

1549 (76)

1493 (75)

1441 (70)

648 (54)

795 (75)

7491 (72)

Quartile 1, fibrinogen value < 25th percentile; Quartile 2, fibrinogen value > 25th percentile and < median; Quartile 3, fibrinogen value ≥ median and < 75th percentile;
Quartile 4, fibrinogen value ≥ 75th percentile
a

Patients who discontinued study treatment/withdrew from the study on or prior to Week 16 and did not have a fibrinogen result at Week 16;

b

Patients who did not discontinue study treatment/withdraw from the study on or prior to Week 16 but had a missing fibrinogen result at Week 16

experienced within the first 16 weeks of the trial: 22–30%
of patients who continued in the trial, and had Week 16
fibrinogen data, experienced an exacerbation within the
first 16 weeks; 46% of patients who withdrew from the
trial on or prior to Week 16, and therefore did not have
fibrinogen data, experienced an exacerbation within
this time period. Differences between Week 16 fibrinogen levels in patients who received FF/UMEC/VI versus
FF/VI (1%), FF/UMEC/VI versus UMEC/VI (2%), and
UMEC/VI versus FF/VI (− 1%) were below the pre-specified ≤ 15% indicating no evidence of a potential treatment effect on Week 16 fibrinogen (Table 4 in Additional
File 1). Based on these results Week 16 Fibrinogen was
considered appropriate to use as baseline measurement.
Efficacy
On‑treatment exacerbation rates

The rates of moderate, moderate/severe, and severe exacerbations increased with increasing fibrinogen quartiles
(Fig. 1). Significant differences (indicated by 95% confidence interval [CI] that did not cross 1) were observed
between the rates of moderate/severe and severe exacerbations for Quartile 4 versus Quartile 1, with rate ratios
of 1.16 and 1.44, respectively (Fig. 1). Similarly, a significant difference was also observed between Quartile 3 and
Quartile 1, with rate ratios of 1.11 and 1.28, for moderate/severe and severe exacerbations, respectively (Fig. 1).
For moderate exacerbations, the difference was significant only for Quartile 4 versus Quartile 1 (rate ratio
1.12) (Fig. 1). When analyzed by treatment arm in each
quartile subgroup, the rate ratio point estimates for moderate, moderate/severe, and severe exacerbations were
generally in favor of FF/UMEC/VI over each dual therapy
(Fig. 2).
Exacerbation rates were also higher in patients with
fibrinogen levels ≥ 3.5 g/L versus < 3.5 g/L, with rate
ratios of 1.08 for moderate/severe exacerbations and
1.30 for severe exacerbations (Fig. 3). Analysis by
treatment group in each fibrinogen threshold subgroup showed that FF/UMEC/VI reduced the rate of

moderate, moderate/severe, and severe exacerbation
versus both FF/VI and UMEC/VI in the low fibrinogen
subgroup (< 3.5 g/L); no significant between-treatment
differences were seen in patients with fibrinogen ≥ 3.5 g/L (Fig. 4).
Analysis of the rate of on-treatment moderate, moderate/severe, and severe exacerbations by continuous fibrinogen levels showed a general trend for an
increased rate of exacerbations with increasing fibrinogen levels in all treatment arms and for all exacerbation
types (Fig. 1 in Additional File 1).
Time‑to‑first on‑treatment exacerbation

Kaplan–Meier plots of time-to-first exacerbation
showed a general trend for increased risk of an ontreatment moderate, moderate/severe, or severe exacerbation with increasing fibrinogen levels (Fig. 5). A
significantly higher risk of moderate/severe (hazard
ratio [HR] [95% confidence interval (CI)]: 1.16 [1.04,
1.28]) and severe (HR: 1.35 [1.09, 1.69]) exacerbations
was seen between patients in fibrinogen Quartile 4
compared with Quartile 1.
Analysis of time-to-first exacerbations using the
3.5 g/L fibrinogen threshold demonstrated a significantly higher risk of on-treatment moderate/severe (HR
[95% CI]: 1.09 [1.00, 1.16]) and severe (HR: 1.27 [1.08,
1.47]) exacerbations in patients with fibrinogen levels ≥ 3.5 g/L compared with those with levels < 3.5 g/L
(Fig. 2 in Additional File 1).
All‑cause mortality

Analysis of ACM showed a similar risk of on-/off-treatment mortality in the highest fibrinogen quartile group
compared with the lower three quartiles (Fig. 6a).
Similarly, analysis of ACM using the fibrinogen 3.5 g/L
threshold showed a similar risk of on-/off-treatment
mortality for fibrinogen levels below and above this
threshold (Fig. 6b).
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Modeled annual rate (95% CI)

Favors
Comparator

Favors
Quartile 1

Comparator

Quartile 1

Rate ratio (95% CI)

Fibrinogen Quartile 2 vs Fibrinogen Quartile 1

0.72 (0.67, 0.78)

0.67 (0.62, 0.72)

1.08 (0.97, 1.20)

Fibrinogen Quartile 3 vs Fibrinogen Quartile 1

0.72 (0.67, 0.78)

0.67 (0.62, 0.72)

1.09 (0.97, 1.20)

Fibrinogen Quartile 4 vs Fibrinogen Quartile 1

0.75 (0.69, 0.80)

0.67 (0.62, 0.72)

1.12 (1.00, 1.25)
0.8

b

Modeled annual rate (95% CI)

Favors
Comparator

1.0

1.2
1.4
1.6
Rate ratio (95% CI)

1.8

2.0

Favors
Quartile 1

Comparator

Quartile 1

Rate ratio (95% CI)

Fibrinogen Quartile 2 vs Fibrinogen Quartile 1

0.86 (0.80, 0.92)

0.79 (0.73, 0.85)

1.09 (0.98, 1.20)

Fibrinogen Quartile 3 vs Fibrinogen Quartile 1

0.88 (0.82, 0.94)

0.79 (0.73, 0.85)

1.11 (1.01, 1.23)

Fibrinogen Quartile 4 vs Fibrinogen Quartile 1

0.92 (0.86, 0.99)

0.79 (0.73, 0.85)

1.16 (1.05, 1.30)
0.8

c

Modeled annual rate (95% CI)

Favors
Comparator

1.0

1.2
1.4
1.6
Rate ratio (95% CI)

1.8

2.0

Favors
Quartile 1

Comparator

Quartile 1

Rate ratio (95% CI)

Fibrinogen Quartile 2 vs Fibrinogen Quartile 1

0.12 (0.10, 0.14)

0.10 (0.09, 0.12)

1.14 (0.89, 1.44)

Fibrinogen Quartile 3 vs Fibrinogen Quartile 1

0.13 (0.11, 0.15)

0.10 (0.09, 0.12)

1.28 (1.01, 1.64)

Fibrinogen Quartile 4 vs Fibrinogen Quartile 1

0.15 (0.13, 0.17)

0.10 (0.09, 0.12)

1.44 (1.14, 1.85)
0.8

1.0

1.2
1.4
1.6
Rate ratio (95% CI)

1.8

2.0

Fig. 1 Rate of on-treatment exacerbations by quartiles. a Moderate; b moderate/severe; c severe. Rate of exacerbations from Week 16 by Week 16
fibrinogen quartiles. Quartile 1, fibrinogen value < 25th percentile; Quartile 2, fibrinogen value > 25th percentile and < median; Quartile 3, fibrinogen
value ≥ median and < 75th percentile; Quartile 4, fibrinogen value ≥ 75th percentile; interaction of treatment with fibrinogen quartile p-values for
a–c are 0.494, 0.515 and 0.916 respectively. CI confidence interval

Safety

Safety data from the IMPACT trial has been previously
published [3]. In this current analysis, incidence of AESIs
were similar across all fibrinogen quartiles. The incidence
of pneumonia was similar (5%) in Quartiles 1, 2 and 3,

but slightly higher (6%) in Quartile 4. For CV events, the
overall incidence was similar in each quartile, but Quartile 4 had a slightly higher event rate (162.7) compared
with Quartiles 1 (139.2), 2 (136.0) and 3 (129.4) (Table 5
in Additional File 1).

(See figure on next page.)
Fig. 2 Rate ratio for on-treatment exacerbations by quartile. a Moderate; b moderate/severe; c severe. Rate ratio (FF/UMEC/VI vs dual therapies)
for on-treatment exacerbations by Week 16 fibrinogen quartile. Quartile 1, fibrinogen value < 25th percentile; Quartile 2, fibrinogen value > 25th
percentile and < median; Quartile 3, fibrinogen value ≥ median and < 75th percentile; Quartile 4, fibrinogen value ≥ 75th percentile. CI confidence
interval; FF fluticasone furoate; n number of patients in the analysis in each subgroup; UMEC umeclidinium; VI vilanterol
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a
FF/UMEC/VI vs FF/VI (n)
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Modeled annual rate (95% CI)

Favors
FF/UMEC/VI

Favors
Dual therapy

Rate ratio (95% CI)

FF/UMEC/VI

FF/VI

Fibrinogen Quartile 1 (827, 769)

0.56 (0.49, 0.64)

0.65 (0.57, 0.73)

0.86 (0.72, 1.04)

Fibrinogen Quartile 2 (803, 818)

0.60 (0.53, 0.68)

0.78 (0.70, 0.88)

0.77 (0.65, 0.91)

Fibrinogen Quartile 3 (853, 776)

0.70 (0.62, 0.79)

0.77 (0.68, 0.87)

0.91 (0.77, 1.07)

Fibrinogen Quartile 4 (866, 802)

0.79 (0.70, 0.88)

0.78 (0.70, 0.88)

1.01 (0.86, 1.17)

FF/UMEC/VI vs UMEC/VI (n)

FF/UMEC/VI

UMEC/VI

Rate ratio (95% CI)

Fibrinogen Quartile 1 (827, 419)

0.56 (0.49, 0.64)

0.64 (0.54, 0.76)

0.87 (0.70, 1.09)

Fibrinogen Quartile 2 (803, 398)

0.60 (0.53, 0.68)

0.76 (0.64, 0.89)

0.80 (0.65, 0.98)

Fibrinogen Quartile 3 (853, 367)

0.70 (0.62, 0.79)

0.81 (0.68, 0.96)

0.87 (0.70, 1.06)

Fibrinogen Quartile 4 (866, 374)

0.79 (0.70, 0.88)

0.83 (0.71, 0.98)

0.94 (0.77, 1.14)
0.4

b
FF/UMEC/VI vs FF/VI (n)

0.6

Modeled annual rate (95% CI)

0.8
1.0
Rate ratio (95% CI)
Favors
FF/UMEC/VI

1.2

Favors
Dual therapy

1.4

Rate ratio (95% CI)

FF/UMEC/VI

FF/VI

Fibrinogen Quartile 1 (827, 769)

0.66 (0.59, 0.75)

0.76 (0.67, 0.86)

0.87 (0.74, 1.03)

Fibrinogen Quartile 2 (803, 818)

0.72 (0.64, 0.80)

0.94 (0.84, 1.04)

0.77 (0.66, 0.89)

Fibrinogen Quartile 3 (853, 776)

0.85 (0.76, 0.95)

0.93 (0.83, 1.04)

0.91 (0.78, 1.06)

Fibrinogen Quartile 4 (866, 802)

0.96 (0.87, 1.06)

0.99 (0.89, 1.10)

0.97 (0.84, 1.12)

FF/UMEC/VI vs UMEC/VI (n)

FF/UMEC/VI

UMEC/VI

Rate ratio (95% CI)

Fibrinogen Quartile 1 (827, 419)

0.66 (0.59, 0.75)

0.78 (0.67, 0.92)

0.85 (0.69, 1.03)

Fibrinogen Quartile 2 (803, 398)

0.72 (0.64, 0.80)

0.91 (0.79, 1.06)

0.79 (0.65, 0.94)

Fibrinogen Quartile 3 (853, 367)

0.85 (0.76, 0.95)

0.98 (0.84, 1.15)

0.87 (0.72, 1.05)

Fibrinogen Quartile 4 (866, 374)

0.96 (0.87, 1.06)

1.02 (0.87, 1.18)

0.95 (0.79, 1.13)
0.4

c
FF/UMEC/VI vs FF/VI (n)

0.6

Modeled annual rate (95% CI)

0.8
1.0
Rate ratio (95% CI)
Favors
FF/UMEC/VI

1.2

Favors
Dual therapy

1.4

Rate ratio (95% CI)

FF/UMEC/VI

FF/VI

Fibrinogen Quartile 1 (827, 769)

0.08 (0.06, 0.11)

0.08 (0.06, 0.11)

0.95 (0.65, 1.39)

Fibrinogen Quartile 2 (803, 818)

0.09 (0.06, 0.12)

0.12 (0.09, 0.16)

0.72 (0.50, 1.06)

Fibrinogen Quartile 3 (853, 776)

0.12 (0.10, 0.16)

0.13 (0.10, 0.17)

0.93 (0.65, 1.33)

Fibrinogen Quartile 4 (866, 802)

0.15 (0.12, 0.19)

0.17 (0.13, 0.21)

0.88 (0.64, 1.22)

FF/UMEC/VI vs UMEC/VI (n)

FF/UMEC/VI

UMEC/VI

Rate ratio (95% CI)

Fibrinogen Quartile 1 (827, 419)

0.08 (0.06, 0.11)

0.11 (0.07, 0.16)

0.73 (0.48, 1.12)

Fibrinogen Quartile 2 (803, 398)

0.09 (0.06, 0.12)

0.12 (0.09, 0.18)

0.69 (0.44, 1.07)

Fibrinogen Quartile 3 (853, 367)

0.12 (0.10, 0.16)

0.14 (0.10, 0.21)

0.87 (0.56, 1.35)

Fibrinogen Quartile 4 (866, 374)

0.15 (0.12, 0.19)

0.16 (0.11, 0.23)

0.91 (0.59, 1.38)
0.4

0.6

0.8
1.0
Rate ratio (95% CI)

1.2

1.4
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Modeled annual rate (95% CI)
Exacerbations

Favors
Fibrinogen ≥3.5g/L

Favors
Fibrinogen <3.5g/L

Fibrinogen ≥3.5g/L

Fibrinogen <3.5g/L

Rate ratio (95% CI)

Moderate

0.73 (0.69, 0.78)

0.71 (0.67, 0.74)

1.03 (0.95, 1.11)

Moderate/severe

0.90 (0.85, 0.95)

0.84 (0.80, 0.88)

1.08 (1.00, 1.15)

Severe

0.14 (0.13, 0.17)

0.11 (0.10, 0.13)

1.30 (1.10, 1.54)

0.8

1.0

1.2
1.4
Rate ratio (95% CI)

1.6

Fig. 3 Rate of on-treatment exacerbations by 3.5 g/L threshold. Rate of on-treatment exacerbations from Week 16 by Week 16 fibrinogen 3.5 g/L
threshold. CI confidence interval

Discussion
This post hoc analysis of the IMPACT trial was undertaken to investigate whether plasma fibrinogen could be
used to stratify a high-risk COPD population and identify
those most likely to have future events. Our findings indicate an increased rate and risk of exacerbation in patients
with higher fibrinogen levels, which is seen regardless of
whether fibrinogen is analyzed by quartiles or by a 3.5 g/L
threshold. In this analysis, higher (≥ 3.5 g/L) versus lower
(< 3.5 g/L) fibrinogen levels were associated with an 8%
increase in exacerbations and a 30% increase in severe
exacerbations (those leading to hospitalisation or death).
The results from this study support the rationale for
using fibrinogen levels as a predictive biomarker for clinical trial recruitment as it provides an indicator of patients
at an increased risk of COPD exacerbations [11]. Patients
in the highest fibrinogen quartile had a 16% increase in
the rate of moderate/severe exacerbations compared
with the lowest quartile. This could be beneficial as an
enrichment strategy in clinical trials looking at exacerbation outcomes, as more exacerbation outputs could
be gained from fewer patients, and fewer patients would
be required to demonstrate treatment effects. However,
it is worth noting that by selecting patients in the highest fibrinogen quartile during clinical trial screening, 75%
of the patient population would be excluded from participating. Importantly, findings from this study support
the utility of fibrinogen as a predictive marker for exacerbations in clinical practice; aiding the identification of a
subgroup of patients with COPD that are at a higher risk
of experiencing exacerbations and would benefit from
appropriate treatment to reduce future risk [4]. A general trend for increased risk of on-treatment moderate,
moderate/severe, and severe exacerbations was observed
with increasing fibrinogen levels for each exacerbation
type, with a more pronounced change seen for severe
exacerbations (i.e. those resulting in hospitalization or

death), than moderate exacerbations. These results are
in agreement with the studies by Mannino et al. [11]
and Kim et al. [12], which reported that higher fibrinogen levels were associated with an increased risk of
exacerbations in patients with COPD, and the study by
Celli et al. [17], which demonstrated an increased risk
of hospitalized exacerbations at higher fibrinogen levels,
although no significant association was seen for moderate/severe exacerbations. The analysis of exacerbations
by continuous fibrinogen levels provides further support
for increased exacerbation rates in patients with higher
fibrinogen levels.
The ACM data showed a similar risk of on-/off-treatment mortality when the highest fibrinogen quartile
group was compared with the lower three quartiles and
when the < 3.5 g/L and ≥ 3.5 g/L fibrinogen subgroups
were compared. This differs from results shown in other
studies that found that higher levels of plasma fibrinogen
were associated with an increased risk of death [11, 17].
These differences could potentially be due to the fact that
the Week 16 fibrinogen population may not represent all
patients; furthermore, patients who died prior to Week
16, and therefore did not have fibrinogen data available,
were not included in this analysis. Finally, it should be
noted that this analysis considers a short duration of follow-up (from Week 16 to Week 52), and that there were
few events, which may have limited power.
The analysis of the rate of exacerbations by treatment
and fibrinogen quartiles showed that rate ratio point
estimates were generally in favor of FF/UMEC/VI versus both dual therapies in all quartile subgroups, with
the most pronounced effect seen in the second quartile
(fibrinogen ≥ 2.780 to < 3.280 g/L), and smaller betweentreatment differences generally seen in the two highest
quartiles. The analysis of exacerbation rates by treatment
and fibrinogen threshold of 3.5 g/L showed a significant
benefit of FF/UMEC/VI over FF/VI and UMEC/VI only
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a

Favors
FF/UMEC/VI

Modeled annual rate (95% CI)
FF/UMEC/VI vs FF/VI (n)

Favors
Dual therapy

FF/UMEC/VI

FF/VI

Rate ratio (95% CI)

Fibrinogen <3.5 g/L (2073, 1966)

0.59 (0.55, 0.64)

0.75 (0.69, 0.81)

0.79 (0.71, 0.88)

Fibrinogen ≥3.5 g/L (1276, 1199)

0.78 (0.72, 0.86)

0.74 (0.68, 0.82)

1.05 (0.93, 1.20)

FF/UMEC/VI

UMEC/VI

Rate ratio (95% CI)

Fibrinogen <3.5 g/L (2073, 994)

0.59 (0.55, 0.64)

0.73 (0.66, 0.82)

0.81 (0.71, 0.92)

Fibrinogen ≥3.5 g/L (1276, 564)

0.78 (0.72, 0.86)

0.80 (0.70, 0.92)

0.97 (0.83, 1.14)

FF/UMEC/VI vs UMEC/VI (n)

0.4

0.6

b

Favors
FF/UMEC/VI

Modeled annual rate (95% CI)
FF/UMEC/VI vs FF/VI (n)

0.8
1.0
Rate ratio (95% CI)

1.2

1.4

Favors
Dual therapy

FF/UMEC/VI

FF/VI

Rate ratio (95% CI)

Fibrinogen <3.5 g/L (2073, 1966)

0.70 (0.65, 0.76)

0.89 (0.83, 0.96)

0.79 (0.71, 0.88)

Fibrinogen ≥3.5 g/L (1276, 1199)

0.96 (0.89, 1.04)

0.93 (0.86, 1.02)

1.03 (0.92, 1.16)

FF/UMEC/VI

UMEC/VI

Rate ratio (95% CI)

Fibrinogen <3.5 g/L (2073, 994)

0.70 (0.65, 0.76)

0.89 (0.81, 0.98)

0.79 (0.70, 0.89)

Fibrinogen ≥3.5 g/L (1276, 564)

0.96 (0.89, 1.04)

0.98 (0.87, 1.11)

0.98 (0.85, 1.14)

FF/UMEC/VI vs UMEC/VI (n)

0.4

0.6

c

Favors
FF/UMEC/VI

Modeled annual rate (95% CI)
FF/UMEC/VI vs FF/VI (n)

0.8
1.0
Rate ratio (95% CI)

1.2

1.4

Favors
Dual therapy

FF/UMEC/VI

FF/VI

Rate ratio (95% CI)

Fibrinogen <3.5 g/L (2073, 1966)

0.09 (0.07, 0.11)

0.11 (0.09, 0.13)

0.82 (0.64, 1.04)

Fibrinogen ≥3.5 g/L (1276, 1199)

0.15 (0.13, 0.19)

0.16 (0.13, 0.20)

0.95 (0.73, 1.24)

FF/UMEC/VI

UMEC/VI

Rate ratio (95% CI)

Fibrinogen <3.5 g/L (2073, 994)

0.09 (0.07, 0.11)

0.13 (0.10, 0.16)

0.70 (0.53, 0.92)

Fibrinogen ≥3.5 g/L (1276, 564)

0.15 (0.13, 0.19)

0.16 (0.12, 0.21)

0.97 (0.69, 1.36)

FF/UMEC/VI vs UMEC/VI (n)

0.4

0.6

0.8
1.0
Rate ratio (95% CI)

1.2

1.4

Fig. 4 Rate ratio for on-treatment exacerbations by 3.5 g/L threshold. a Moderate; b moderate/severe; c severe. Rate ratio (FF/UMEC/VI vs dual
therapies) for on-treatment exacerbations by Week 16 fibrinogen 3.5 g/L threshold. CI confidence interval; FF fluticasone furoate; n number of
patients in the analysis in each subgroup; UMEC umeclidinium; VI vilanterol
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224
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1312
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1337
1244
1233
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1275
1189
1176
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1840
1831
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Fig. 5 Time-to-first on-treatment exacerbation by quartile. a Moderate; b moderate/severe; c severe. Time-to-first on-treatment exacerbation from
Week 16 by Week 16 fibrinogen quartile. Interaction of treatment with fibrinogen quartile p-values for a–c are 0.695, 0.599 and 0.783 respectively:
Quartile 1: < 2.780 g/L; Quartile 2: ≥ 2.780 g/L; Quartile 3: < 3.830 g/L; Quartile 4: ≥ 3.830 g/L
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Probability of event (%)
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0.8
0.6
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0
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5045
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5039
3046

5034
3040

5025
3031
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3023

4998
3020

Fig. 6 All-cause mortality on and off-treatment by a fibrinogen quartile; b fibrinogen 3.5 g/L threshold. Quartile 1: < 2.780 g/L; Quartile
2: ≥ 2.780 g/L; Quartile 3: < 3.830 g/L; Quartile 4: ≥ 3.830 g/L

in patients with fibrinogen < 3.5 g/L. The explanation for
this is unclear. Due to the lack of data before Week 16,
these results should be interpreted with caution as this
limits inferences that may be made around treatment
effect; there was a lower rate of treatment discontinuation in patients treated with triple versus dual therapy
[3], possibly confounding any potential treatment effects.
Finally, patients with higher fibrinogen levels had more
exacerbations, and it is possible to speculate that these

could be biologically different events that did not respond
as well to ICS.
Fibrinogen is a known risk factor in CV disease,
and fibrinogen levels have been shown to be higher in
patients with CV disease than those without [18]. In
our analyses, the highest fibrinogen quartile had similar
incidence of CV events compared with the other quartiles, with only a small increase in annual event rate
(0.16 event per patient-year in the highest quartile vs
0.13–0.15 in the other quartiles). Only SAEs and deaths
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were independently adjudicated in the IMPACT trial;
therefore, the lack of an observable increase in AESIs
with increasing levels of fibrinogen in our analysis could
potentially be due to AEs being misclassified by the clinician as respiratory in nature when in fact they were CV
events because of overlapping clinical symptoms between
the diseases [19, 20].
Systemic inflammation has been associated with CV
disease, cancer, and metabolic syndrome as well as
COPD [9, 21–23]. The relationship between reduced
fibrinogen and protection from exacerbations [9, 11, 24],
suggests that there might be a low-grade inflammatory
condition in the lung or extrapulmonary that predisposes
patients to exacerbations. It is well known that ICS and
LABA therapy can reduce exacerbations in patients with
a low risk of exacerbations [25]. However, the absence of
an effect of treatment on fibrinogen levels suggests that
the site of this ongoing inflammatory response may not
reside in the lung. It should be noted that patients with
COPD may also suffer from comorbid diseases that could
drive an increase in fibrinogen levels, such as cardiac failure or diabetes; therefore, higher fibrinogen levels may
also be an indicator of a comorbidity [4].
The sample size for the IMPACT trial was large allowing for these subgroup analyses; however, there are limitations that should be considered when interpreting
these data. Fibrinogen data were only collected at Week
16. This is supported by previous studies that had shown
that treatment with oral steroids [16] or ICS/LABA [15]
did not have an effect on fibrinogen levels. However, it
is worth noting that the exacerbation incidence within
the first 16 weeks was higher in patients who withdrew
from the study compared with those who remained in the
study. Furthermore, 2261 patients did not have fibrinogen
data; had data been available for these patients, a different result may have been observed. Additionally, survival
bias may mean that patients included in this analysis are
not representative of a general patient population with
COPD. Furthermore, overall data from the IMPACT trial
indicates there was a clear separation between treatment
arms for both moderate or severe exacerbations and
mortality by Week 16, with ACM significantly lower for
FF-containing therapies, which could have influenced the
results [3].

Conclusions
In this post hoc analysis of fibrinogen levels in the
IMPACT trial, higher fibrinogen levels in patients with
COPD were associated with a higher rate and risk of
exacerbations. There appeared to be no association
between fibrinogen levels and risk of death, although
the lack of data prior to Week 16 and the relatively
small number of deaths overall limit interpretation
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on risk of death, in addition to the assessment of any
potential treatment effects. The incidence of AESIs was
similar between fibrinogen levels, with pneumonia and
CV events slightly more common at the highest fibrinogen quartile. Overall, our findings confirm the utility
of fibrinogen as a predictive biomarker of exacerbation
risk but not for risk of mortality.
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